|
At Risk of
Having Your Dry AMD Progress to Wet AMD?
News about a Clinical Trial.
Did you know
that sometimes dry AMD can progress to
wet AMD? Did you know that everyone who
has wet AMD started out with dry AMD? For most people with dry AMD,
however, dry AMD does not become wet AMD, however, dry AMD does
not become wet AMD. So who?s at risk? People who have wet AMD in
one eye are at especially high risk of developing wet AMD in the
other eye.
Alcon Research
Ltd. is conducting a clinical study to evaluate the safety and effectiveness
of treatment with the investigational drug Anecortave Acetate for
stopping the progression of dry AMD to wet AMD. People eligible
to participate in this clinical study must be 50 years of age or
older, currently have (or have previously had) wet AMD in one eye
and have at-risk dry AMD that meets certain clinical characteristics
in the other eye. In addition to an initial screening visit, eligible
subjects will visit their eye doctor twice a year for four years
to receive study treatments and examinations.
Subjects enrolled
in the stuffy will not know whether they are receiving Anecortave
Acetate or the sham procedure, which imitates the investigational
drug. During the eight visits that will occur over the course of
the study, subjects will receive thorough study-related eye exams
at no costs.
To find out
if you can be part of this clinical study, call toll free 1-866-692-5959,
send e-mail to wetamd@inversesk.com
or visit www.alconlabs.com
Protocol Number C-02-60 Information for Potential Participants
About Phase III Clinical Trial to Evaluate an Investigational treatment
for stopping the Progression of Dry AMD to Wet AMD
Alcon Research,
Ltd. is conducting a clinical trial to evaluate the safety and effectiveness
of treatment with investigational drug Anecortave Acetate compared
to a sham procedure. Eligible patients must currently have (or have
previously had) wet AMD in one and dry AMD in the other eye, and
be at risk of having their dry AMD progress to wet AMD. The purpose
of the study is to evaluate the safety and effectiveness of Anecortave
Acetate in stopping the progression of dry AMD to wet AMD.
For additional
information about participating in this clinical trial, call toll-free
1 866-692-5959 or email us at wetamd@inversk.com
or visit www.alconlabs.com
Dr.
James Kimble, MD will serve as principal investigator for the
Alcon Anecortave Acetate Risk Reduction phase III clinical trial
in Birmingham, Alabama.
Patient Info|Physician Info|FILMS|
RSA Research|RSA
Physicians|RSA Facilities |Resources
Contact us at 205-933-2625 or 800-292-8166
Margaret Harrill -
Web Master
-
rev
April 2006
Study
Enrollment Completed
February
2006
This Site Contains Copyrighted Text And Graphics
Photos courtsey of Red Atlas
© Copyright 2000 Retina Specialists of Alabama, LLC
Illustrations - ©
Steve Gordon
| 
